Lead Candidate
Acura and King are developing Acurox® (oxycodone HCl) Tablets (without niacin) intended to relieve moderate to severe pain and to introduce limits and impediments to potential abuse via nasal snorting of crushed tablets and intravenous injection of dissolved tablets. The FDA cited no concerns with the snorting and intravenous abuse limiting features of Acurox® with Niacin (oxycodone HCl/niacin) Tablets. Submission of an NDA for Acurox® Tablets is expected in early 2011.
Collaboration
Acura has entered into a license agreement with King Pharmaceuticals, Inc. to develop and commercialize opioid analgesic products utilizing our proprietary Aversion® Technology, including Acurox® Tablets.
Innovation
Acura’s strategy includes continued investment in novel solutions to prescription drug abuse. We have three issued U.S. patents covering our Aversion® Technology with numerous US and international patent applications pending.